Healthcare provider profile · identity verified

Brian Keith Gamble, M.D.

Allopathic & Osteopathic Physicians|Radiology|Diagnostic Radiology · TOLUCA LAKE, CA · NPI 1568478436

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Brian Keith Gamble, M.D. received $538.55 in general payments during 2025 across 24 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 51.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 5 associated products.

Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Descovy by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$538.55

24 reported records · 5 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$279.32	51.9%	14	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$82.42	15.3%	3	2025
Xeris Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$60.05	11.2%	3	2025
Gilead Sciences, Inc.	Unresolved — no canonical attribution shown	$59.75	11.1%	2	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$57.01	10.6%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$538.55	24

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$279.32	14	2025
Source payment records 2025-02-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.30 · Open Payments source 2025-04-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.40 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.32 · Open Payments source 2025-07-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.24 · Open Payments source 2025-07-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.33 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.69 · Open Payments source 2025-09-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.44 · Open Payments source 2025-09-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.29 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.91 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.94 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.15 · Open Payments source 2025-11-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.95 · Open Payments source 2025-12-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.50 · Open Payments source 2025-12-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.86 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$82.42	3	2025
Source payment records 2025-05-14 · Teva Pharmaceuticals USA, Inc. · $25.02 · Open Payments source 2025-07-01 · Teva Pharmaceuticals USA, Inc. · $30.70 · Open Payments source 2025-07-28 · Teva Pharmaceuticals USA, Inc. · $26.70 · Open Payments source
GVOKE HYPOPEN Normalized: gvoke hypopen	Drug	Xeris Pharmaceuticals, Inc.	$60.05	3	2025
Source payment records 2025-04-17 · Xeris Pharmaceuticals, Inc. · $17.20 · Open Payments source 2025-08-19 · Xeris Pharmaceuticals, Inc. · $21.13 · Open Payments source 2025-12-04 · Xeris Pharmaceuticals, Inc. · $21.72 · Open Payments source
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$57.01	2	2025
Source payment records 2025-03-20 · Lilly USA, LLC · $28.08 · Open Payments source 2025-05-30 · Lilly USA, LLC · $28.93 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$57.01	2	2025
Source payment records 2025-03-20 · Lilly USA, LLC · $28.08 · Open Payments source 2025-05-30 · Lilly USA, LLC · $28.93 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Gilead Sciences, Inc. Exact reporting entity; no affiliate inference	2025	Descovy open payments reported associated product	CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196	Descovy · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	58	29

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	550	188
Atorvastatin Calcium	Atorvastatin Calcium	539	181
Gabapentin	Gabapentin	353	122
Albuterol Sulfate Hfa	Albuterol Sulfate	346	158
Metformin Hcl	Metformin Hcl	338	124
Omeprazole	Omeprazole	271	98
Losartan Potassium	Losartan Potassium	266	89
Ibuprofen	Ibuprofen	263	95
Tamsulosin Hcl	Tamsulosin Hcl	260	103
Lisinopril	Lisinopril	233	83
Furosemide	Furosemide	221	75
Hydrochlorothiazide	Hydrochlorothiazide	207	77
Quetiapine Fumarate	Quetiapine Fumarate	158	44
Carvedilol	Carvedilol	149	39
Trazodone Hcl	Trazodone Hcl	142	40
Levothyroxine Sodium	Levothyroxine Sodium	135	46
Glipizide	Glipizide	125	45
Alprazolam	Alprazolam	119	23
Sertraline Hcl	Sertraline Hcl	105	33
Pantoprazole Sodium	Pantoprazole Sodium	97	35
Metoprolol Succinate	Metoprolol Succinate	91	32
Diclofenac Sodium	Diclofenac Sodium	90	33
Mirtazapine	Mirtazapine	89	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	80	35
Metoprolol Tartrate	Metoprolol Tartrate	78	27
Benazepril Hcl	Benazepril Hcl	76	16
Ciprofloxacin Hcl	Ciprofloxacin Hcl	75	56
Allopurinol	Allopurinol	74	27
Montelukast Sodium	Montelukast Sodium	73	24
Eliquis	Apixaban	72	23
Escitalopram Oxalate	Escitalopram Oxalate	71	16
Rosuvastatin Calcium	Rosuvastatin Calcium	71	26
Nifedipine Er	Nifedipine	70	21
Meloxicam	Meloxicam	69	25
Clopidogrel	Clopidogrel Bisulfate	68	24
Donepezil Hcl	Donepezil Hcl	68	21
Duloxetine Hcl	Duloxetine Hcl	68	17
Ventolin Hfa	Albuterol Sulfate	68	28
Finasteride	Finasteride	67	18
Naproxen	Naproxen	67	20
Fluticasone Propionate	Fluticasone Propionate	66	28
Potassium Chloride	Potassium Chloride	65	23
Hydrocortisone	Hydrocortisone	64	28
Hydroxyzine Hcl	Hydroxyzine Hcl	64	16
Lorazepam	Lorazepam	63	14
Jardiance	Empagliflozin	58	29
Ozempic	Semaglutide	57	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	56	16
Januvia	Sitagliptin Phosphate	53	18
Simvastatin	Simvastatin	53	18
Zolpidem Tartrate	Zolpidem Tartrate	53	14
Ondansetron Hcl	Ondansetron Hcl	50	20
Clonidine Hcl	Clonidine Hcl	49	16
Famotidine	Famotidine	49	20
Fluoxetine Hcl	Fluoxetine Hcl	47	11
Oxybutynin Chloride	Oxybutynin Chloride	47	15
Diazepam	Diazepam	45	suppressed
Levetiracetam	Levetiracetam	45	13
Metformin Er Gastric	Metformin Hcl	45	suppressed
Hydralazine Hcl	Hydralazine Hcl	42	13
Prednisone	Prednisone	42	18
Aripiprazole	Aripiprazole	40	12
Alendronate Sodium	Alendronate Sodium	39	17
Citalopram Hbr	Citalopram Hydrobromide	39	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	38	12
Ezetimibe	Ezetimibe	35	11
Lamotrigine	Lamotrigine	35	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	34	18
Amoxicillin	Amoxicillin	33	27
Glimepiride	Glimepiride	33	13
Nitroglycerin	Nitroglycerin	33	15
Bupropion Xl	Bupropion Hcl	32	suppressed
Memantine Hcl	Memantine Hcl	31	15
Risperidone	Risperidone	31	suppressed
Spironolactone	Spironolactone	31	12
Xarelto	Rivaroxaban	31	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	30	suppressed
Baclofen	Baclofen	29	16
Atenolol	Atenolol	28	11
Fluconazole	Fluconazole	28	12
Alcohol Prep Pads	Alcohol Antiseptic Pads	27	14
Amitriptyline Hcl	Amitriptyline Hcl	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	20
Clonazepam	Clonazepam	26	suppressed
Dexlansoprazole Dr	Dexlansoprazole	26	suppressed
Propranolol Hcl	Propranolol Hcl	26	suppressed
Clobetasol Propionate	Clobetasol Propionate	25	suppressed
Clotrimazole	Clotrimazole	25	15
Meclizine Hcl	Meclizine Hcl	25	12
Valsartan	Valsartan	25	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	25	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	24	suppressed
Omeprazole-Sodium Bicarbonate	Omeprazole/Sodium Bicarbonate	24	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	24	suppressed
Colchicine	Colchicine	23	11
Darunavir	Darunavir	23	suppressed
Latanoprost	Latanoprost	23	suppressed
Pregabalin	Pregabalin	23	12
Carbamazepine	Carbamazepine	22	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	22	suppressed
Diclofenac Potassium	Diclofenac Potassium	22	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	22	suppressed
Linzess	Linaclotide	22	suppressed
Lurasidone Hcl	Lurasidone Hcl	22	suppressed
Azithromycin	Azithromycin	21	21
Glipizide Er	Glipizide	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Tramadol Hcl	Tramadol Hcl	21	13
Buspirone Hcl	Buspirone Hcl	20	suppressed
Myrbetriq	Mirabegron	20	suppressed
Atrovent Hfa	Ipratropium Bromide	19	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Perphenazine	Perphenazine	19	suppressed
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	18	suppressed
Celecoxib	Celecoxib	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Methocarbamol	Methocarbamol	17	suppressed
Spiriva Respimat	Tiotropium Bromide	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Benztropine Mesylate	Benztropine Mesylate	16	suppressed
Descovy	Emtricitabine/Tenofov Alafenam	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Loperamide	Loperamide Hcl	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	15
Arnuity Ellipta	Fluticasone Furoate	15	suppressed
Bethanechol Chloride	Bethanechol Chloride	15	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Metronidazole	Metronidazole	14	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	11
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Single Use Swab	Alcohol Antiseptic Pads	14	suppressed
Alogliptin	Alogliptin Benzoate	13	suppressed
Clemastine Fumarate	Clemastine Fumarate	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	13	suppressed
Tavaborole	Tavaborole	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Ritonavir	Ritonavir	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Anastrozole	Anastrozole	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Methimazole	Methimazole	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Tivicay	Dolutegravir Sodium	11	suppressed
Tradjenta	Linagliptin	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$538.55 · 24 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	AUSTEDO XR, CAPLYTA, GVOKE HYPOPEN, MOUNJARO, ZEPBOUND	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error